This study demonstrates that higher exposure to abatacept can reduce the occurrence of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors (URDs), without increasing the risk of relapse.
In this issue of Blood, Takahashi et al(1) show that higher abatacept exposure decreases the occurrence of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors (URDs), without increasing the risk of relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
